Physician profile
Stanley E Watkins
NPI 1902802952
$5,749.52
in general payments reported to CMS, 2019-2025
25 companies · $822 in 2025
The $822 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $751 · 2021: $848 · 2022: $762 · 2023: $839 · 2024: $975 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,351.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $585.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $459.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $394.66 | 2019-2025 | |
| Abbvie INC. | $350.01 | 2019-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $276.18 | 2019-2023 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $249.88 | 2022-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $192.71 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $184.05 | 2020-2022 | |
| Edwards Lifesciences Corporation | $106.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $102.62 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.98 | 2019-2022 | |
| Abbott Laboratories | $68.40 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $53.05 | 2019-2020 | |
| Allergan, INC. | $49.96 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $37.92 | 2022 | |
| Dexcom, INC. | $35.19 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $31.35 | 2021 | |
| Eisai INC. | $30.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.76 | 2022 | |
| Exact Sciences Corporation | $18.19 | 2025 | Cologuard Collection Kit |
| Depuy Synthes Sales INC. | $16.65 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.32 | 2020 | |
| Corium, LLC | $10.41 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.